The future of cancer care: A bird’s-eye view

The recent World Medical Innovation Forum on Cancer convened by Partners Healthcare in Boston was attended by leaders in oncology from around the world including top: clinicians, bench scientists, policy leaders, and executives from hospitals and life-science companies.  Two plus days of intense discussion and sharing of perspectives ably curated by Partners Innovation head Chris Coburn covered a range of topics from technology developments, to the healthcare system, and the patient/ doctor perspectives.

The mind-map below is an attempt to organize the key themes that I heard through the conference and to try to convey why I came away feeling incredibly optimistic about the future of cancer care.

The branches on the left hand side relate to how clinical care will evolve. We will see an increasing focus on patient centered care, incredible advances in life expectancy with cancer thanks to novel technologies, and ever increasing complexity for clinicians.

The branches on the right relate to how the healthcare system will need to evolve to continue to advance the science and best serve the needs of patients and doctors. We need to see more collaboration, continued funding, new regulatory frameworks, and a sustainable economic model.

 

2016-05-19 Future of oncology For Web

Share

Keep up with the Recon Strategy Insights

Get an email each time Recon takes an analytical look behind select developments in healthcare.

Suggested Articles

Preempting severe genetic disease Around 2% of births come with a genetic disease, often with devastating impact. While some appear de novo (either from germplasm dominant mutations or from chromosoma…
Summary: Over the coming decades, Alzheimer’s disease threatens to become a huge drag on national well-being. To put things in perspective, by 2040, the US may be allocating more resources to the care…
“media attention [is] on lead identification, probably because it sells headlines” –  Greg Meyers, Chief Digital and Technology Officer, BMS[1] The biopharma industry is known for its high risk and po…
We use cookies
This website collects cookies to deliver better user experience and to analyze our website traffic and performance; we never collect any personal data or target you with ads.